Mi­rati and Am­gen un­wrap new KRAS tri­al da­ta, set­ting the stage for po­ten­tial com­bo treat­ments: #ES­MO23

MADRID — While suc­cess­ful in tar­get­ing one of the most elu­sive can­cer dri­vers, KRAS in­hibitors have failed to gen­er­ate huge up­take by them­selves. The com­pa­nies that …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER